Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113580 | 0.89 | FAAH (0.39) | FAAHBCHEPTGS1PTGS2TSHR | |
| SCHEMBL20104906 | 0.88 | HPGD (0.42) | CNR1PTGS1PTGS2 | |
| SCHEMBL20104867 | 0.84 | HPGD (0.39) | PTGS1PTGS2MMP2MMP9MMP8 | |
| SCHEMBL18115163 | 0.83 | CA1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL13397048 | 0.81 | NOD1 (0.42) | NOD1 | |
| SCHEMBL13396744 | 0.80 | NOD1 (0.44) | NOD1 | |
| SCHEMBL20104905 | 0.80 | CASP2 (0.38) | CNR1FAAHCASP2BCHEPTGS1 | |
| SCHEMBL13863668 | 0.79 | TSHR (0.41) | PTGS1PTGS2TSHR | |
| SCHEMBL20104860 | 0.79 | ALDH1A1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL13396641 | 0.79 | PTPN1 (0.45) | FAAHPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | CNR1 2037/4885FAAH 2843/4885CASP2 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.